UNSPSC 51332865: Perphenazine hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C21H26ClN3OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 667C5N7677, chemically known as 1-piperazineethanol, 4-(3-(2-chloro-10h-phenothiazin-10-yl)propyl)-, hydrochloride (1:1), but more generally known as perphenazine hydrochloride, which bears US NIH Compound Identifier 76557. European Medicines Agency schedules perphenazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG.

Most nations, for tariff purposes, schedule perphenazine hydrochloride under HS 29343090. SMILES: C1CCC2C(C1)N(C3C(CCCC3CL)S2)CCCN4CCN(CC4)CCO.CL.

UNSPSC 51332865 Perphenazine hydrochloride, a Commodity-tier code, shows minimal alignment with recent state and local procurement activity. The code nominally denotes a specific antipsychotic pharmaceutical product, but the three opportunities currently tagged to it involve naloxone procurement, direct-to-manufacturer pharmacy initiative planning, and multi-source generic pharmaceutical contracting — none of which center on perphenazine hydrochloride as the primary buy. The mismatch suggests either broad misclassification in the tagging systems of the issuing bodies or that perphenazine hydrochloride is one among many pharmaceutical SKUs bundled into broader pharmaceutical supply agreements that carry the code nominally but do not actively solicit it by name. State and local buyers pursuing pharmaceutical contracting do so through health departments, pharmacy benefit administrators, and cooperative purchasing alliances rather than targeting individual active ingredients.

Recent opportunities involve Seminole County, Florida (IFB for naloxone and drug deactivation systems, response due July 26, 2023), the Texas Health and Human Services Commission (RFI on direct-to-manufacturer prescription programs, response due April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (RFP for generic multi-source pharmaceuticals and OTC products, response due March 26, 2026). Activity concentrates in Florida, Texas, and the upper Midwest, with MMCAP representing coordinated multi-state demand. The code shows little decision-relevant recent procurement activity specific to perphenazine hydrochloride itself; firms pursuing pharmaceutical sales to state and local buyers should focus on broader pharmaceutical supply, wholesale distribution, and cooperative purchasing frameworks rather than expecting dedicated solicitations keyed to individual drug molecules.